Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FAP | Q12884 | 5/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13217421 | 0.89 | MEN1 (0.48) | DPP4CHRM1MEN1KMT2A | |
| SCHEMBL2964814 | 0.86 | DPP4 (0.55) | DPP4CHRM1FAP | |
| Trifluoroacetic Acid SCHEMBL2964812 | 0.85 | DPP4 (0.60) | DPP4CHRM1FAPDPP9 | |
| SCHEMBL13200876 | 0.84 | LMNA (0.54) | DPP4CHRM1MEN1KMT2A | |
| SCHEMBL13200747 | 0.83 | DPP4 (0.72) | DPP4CHRM1FAPDPP9 | |
| SCHEMBL13200737 | 0.83 | DPP4 (0.63) | DPP4CHRM1FAP | |
| SCHEMBL13200764 | 0.83 | DPP4 (0.59) | DPP4CHRM1FAP | |
| SCHEMBL13200779 | 0.82 | DPP4 (0.64) | DPP4CHRM1FAPDPP9 | |
| SCHEMBL13200795 | 0.82 | DPP4 (0.62) | DPP4CHRM1FAP | |
| SCHEMBL13200776 | 0.82 | DPP4 (0.60) | DPP4CHRM1FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | DPP4, HDAC1, DPP7 | DPP4 1/4885CHRM1 43/4885MEN1 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.